The α7 nicotinic acetylcholine receptor (nAChR) is a promising target for the treatment of cognitive deficits associated with psychiatric and neurological disorders, including schizophrenia and Alzheimer’s disease (AD). Several α7 nAChR agonists and positive allosteric modulators (PAMs) have demonstrated procognitive effects in preclinical models and early clinical trials. However, despite intense research efforts in the pharmaceutical industry and academia, none of the α7 nAChR ligands has been approved for clinical use. This chapter will focus on the α7 nAChR ligands that have advanced to clinical studies and explore the reasons why these agents have not met with unequivocal clinical success.
CITATION STYLE
Wang, X., Bell, I. M., & Uslaner, J. M. (2020). Activators of α7 nAChR as potential therapeutics for cognitive impairment. In Current Topics in Behavioral Neurosciences (Vol. 45, pp. 209–245). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/7854_2020_140
Mendeley helps you to discover research relevant for your work.